![]() |
|
|
Vol. 281, Issue 2, 921-927, 1997
Pharmaceuticals Laboratory 2 (H.K.),
Pharmaceuticals Laboratory 1 (M.S., S.Y., T.W., K.S.), and
Pharmacokinetics and Drug Metabolism
Laboratory (H.N.), Yokohama Research Center, Mitsubishi Chemical
Corporation, 1000, Kamoshida-cho, Aoba-ku Yokohama 227, Japan
We investigated the effects of a free radical scavenger,
3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), on infarct areas, neurological deficits and regional cerebral blood flow (rCBF), with use
of a rat thrombotic distal middle cerebral artery (dMCA) occlusion
model to elucidate its possible therapeutic effects on focal cerebral
ischemia. In addition, we have attempted to measure
2-oxo-3-(phenylhydrazono)-butanoic acid (OPB), which is the major
oxidation product of MCI-186, in the penumbral cortex of a thrombotic
dMCA occlusion model. Postischemic treatment with MCI-186 (3 mg/kg)
significantly (P < .05) decreased the size of the cerebral
infarcts 1 day after dMCA occlusion. MCI-186 (3 mg/kg) significantly
(P < .05) improved the neurological deficits 1 day after dMCA
occlusion. On the contrary, MCI-186 had no effect on rCBF 1 day after
dMCA occlusion. MCI-186 mainly reacted into OPB by peroxidation in rat
brain homogenates. Furthermore, the increase in OPB content in the
ischemic penumbral cortex tissue was confirmed after 90 min of MCI-186
perfusion. These results suggest that MCI-186 has a protective effect
on brain ischemia by reacting with oxygen radicals and that oxygen
radicals are closely related to postischemic brain injury.